Ocular Therapeutix (NASDAQ:OCUL) COO Donald Notman Sells 5,455 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 5,455 shares of Ocular Therapeutix stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.14, for a total transaction of $49,858.70. Following the transaction, the chief operating officer directly owned 383,837 shares of the company’s stock, valued at $3,508,270.18. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The stock was sold at an average price of $8.54, for a total transaction of $51,538.90.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $8.55 on Thursday. Ocular Therapeutix, Inc. has a 1-year low of $5.78 and a 1-year high of $16.44. The company’s 50-day moving average is $11.94 and its 200 day moving average is $11.97. The firm has a market capitalization of $1.82 billion, a P/E ratio of -5.94 and a beta of 0.90. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.05. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%.The firm had revenue of $13.25 million for the quarter. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s quarterly revenue was down 22.4% compared to the same quarter last year. Research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on OCUL shares. Wall Street Zen downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. TD Cowen reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $20.00 price objective on shares of Ocular Therapeutix in a report on Monday, December 8th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a report on Wednesday, November 5th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Ocular Therapeutix has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Institutional Investors Weigh In On Ocular Therapeutix

A number of large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,392 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 893 shares in the last quarter. KBC Group NV acquired a new stake in shares of Ocular Therapeutix during the 4th quarter valued at about $78,000. Quarry LP purchased a new position in shares of Ocular Therapeutix in the 3rd quarter valued at about $80,000. Finally, Trust Co. of Vermont raised its holdings in Ocular Therapeutix by 24.3% in the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.